risks semaglutide Semaglutide: What we know about safety and cancer risk A real‐world disproportionality analysis of

The net benefit of GLP-1 receptor agonists in adults with overweight or obesity who do not have diabetes depends on their weight loss target and willingness to accept harms, according to researchers.Although GLP-1 receptor agonists have demonstrated effectiveness in reducing weight loss and risks for other chronic diseases, questions remain over whether the benefits outweigh the harms of the

Longitudinal Targeted Minimum Loss-based Estimation, a method that adjusts for both baseline and time-varying confounding, was used to estimate absolute risks of cardiovascular outcomes under sustained use of GLP1-RA and DPP 4i (active comparator), adjusting for baseline and time-varying confounding

Learn exactly where to give a GLP-1 shot in the arm with this comprehensive UK guide

People taking Mounjaro may feel exhausted due to low blood sugar, eating less food than usual, and having stomach side effects

An indepth look at can amoxicillin make you tired, covering how it is used, how it works, potential side effects, and practical points to discuss with your doctor.

LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial @TheLancet @LillyTrials #Retatrutide